← Leaderboards
Bo Han
Ceremed, Inc.
$356,385
Attributed
$356,385
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $99.8K · FY2009–20$100K$75K$50K$25K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$356,385 · 2
By mechanism
U54$256,597 · 1
R41$99,788 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoEffectivenessTumorBiologicalCharacteristicsBaseOperative Surgical ProceduresTissuesBloodSurfaceAmino GroupAffectCaucasiansCessation Of LifeChemosensitizationCancer Health DisparityBiopsyCancer EtiologyCancer PatientCancer CellAnticancer ResearchCancer GenomeAntineoplastic AgentsCancer Diagnosis
Grant awards (4)
Project 2: Enhancing Efficacy of Gemcitabine Nanoparticles in Pancreatic PDX Models$95,816
U54 · FY2020 · CA · contact PI
Project 2: Enhancing Efficacy of Gemcitabine Nanoparticles in Pancreatic PDX Models$92,318
U54 · FY2019 · CA · contact PI
Project 2: Enhancing Efficacy of Gemcitabine Nanoparticles in Pancreatic PDX Models$68,463
U54 · FY2018 · CA · contact PI
Novel Bone Graft Material With Osteoinductive and Hemostatic Function$99,788
R41 · FY2009 · AR · contact PI